Mednax, Inc (NYSE:MD) has earned a consensus recommendation of “Hold” from the fifteen brokerages that are covering the stock, MarketBeat Ratings reports. Two analysts have rated the stock with a sell recommendation, eleven have given a hold recommendation and one has assigned a buy recommendation to the company. The average 1 year price objective among brokerages that have updated their coverage on the stock in the last year is $62.38.

Several equities analysts have recently commented on MD shares. Mizuho reduced their price target on shares of Mednax from $64.00 to $58.00 and set a “neutral” rating on the stock in a research report on Tuesday, May 30th. Jefferies Group LLC reaffirmed a “hold” rating and set a $58.00 price target on shares of Mednax in a research report on Wednesday, April 26th. TheStreet cut shares of Mednax from a “b-” rating to a “c+” rating in a research report on Tuesday, May 16th. BidaskClub raised shares of Mednax from a “sell” rating to a “hold” rating in a research report on Friday, June 23rd. Finally, Stephens raised shares of Mednax from an “equal weight” rating to an “overweight” rating and increased their price target for the stock from $55.00 to $68.00 in a research report on Thursday, June 22nd.

ILLEGAL ACTIVITY NOTICE: This report was first reported by Watch List News and is the property of of Watch List News. If you are accessing this report on another website, it was copied illegally and reposted in violation of US & international trademark & copyright legislation. The original version of this report can be accessed at https://www.watchlistnews.com/mednax-inc-md-receives-average-recommendation-of-hold-from-analysts/1473363.html.

Mednax (MD) traded up 1.54% during mid-day trading on Friday, reaching $42.75. The company’s stock had a trading volume of 459,195 shares. The stock’s 50 day moving average price is $54.64 and its 200 day moving average price is $61.63. The stock has a market capitalization of $3.94 billion, a P/E ratio of 13.61 and a beta of 0.40. Mednax has a 1-year low of $41.52 and a 1-year high of $72.13.

Mednax (NYSE:MD) last posted its quarterly earnings data on Friday, July 28th. The company reported $0.85 earnings per share for the quarter, beating analysts’ consensus estimates of $0.81 by $0.04. The company had revenue of $843 million during the quarter, compared to analysts’ expectations of $849.49 million. Mednax had a net margin of 8.78% and a return on equity of 11.89%. The firm’s revenue for the quarter was up 9.2% on a year-over-year basis. During the same period in the prior year, the company posted $1.03 EPS. Analysts expect that Mednax will post $3.31 EPS for the current fiscal year.

In related news, insider Joseph M. Calabro sold 23,327 shares of the stock in a transaction dated Thursday, June 1st. The shares were sold at an average price of $55.00, for a total transaction of $1,282,985.00. Following the sale, the insider now owns 296,379 shares in the company, valued at $16,300,845. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Md Pascal J. Goldschmidt sold 1,969 shares of the stock in a transaction dated Wednesday, June 14th. The stock was sold at an average price of $57.57, for a total transaction of $113,355.33. Following the sale, the director now owns 18,072 shares in the company, valued at approximately $1,040,405.04. The disclosure for this sale can be found here. 2.40% of the stock is owned by corporate insiders.

A number of large investors have recently added to or reduced their stakes in MD. BlackRock Inc. raised its stake in Mednax by 5,766.0% in the first quarter. BlackRock Inc. now owns 8,229,340 shares of the company’s stock valued at $570,952,000 after buying an additional 8,089,052 shares during the period. Thompson Siegel & Walmsley LLC raised its stake in Mednax by 95.9% in the second quarter. Thompson Siegel & Walmsley LLC now owns 2,170,741 shares of the company’s stock valued at $131,048,000 after buying an additional 1,062,584 shares during the period. Schroder Investment Management Group raised its stake in Mednax by 144.1% in the first quarter. Schroder Investment Management Group now owns 1,734,697 shares of the company’s stock valued at $120,458,000 after buying an additional 1,024,048 shares during the period. Longview Partners Guernsey LTD raised its stake in Mednax by 27.4% in the first quarter. Longview Partners Guernsey LTD now owns 4,555,631 shares of the company’s stock valued at $316,070,000 after buying an additional 980,081 shares during the period. Finally, Victory Capital Management Inc. raised its stake in Mednax by 62.9% in the first quarter. Victory Capital Management Inc. now owns 1,977,791 shares of the company’s stock valued at $137,219,000 after buying an additional 763,633 shares during the period.

About Mednax

MEDNAX, Inc is a provider of physician services, including newborn, anesthesia, maternal-fetal, teleradiology, pediatric cardiology and other pediatric subspecialty care. As of December 31, 2016, the Company’s national network consisted of over 3,600 affiliated physicians, including over 1,130 physicians providing neonatal clinical care, in 35 states and Puerto Rico, primarily within hospital-based neonatal intensive care units (NICUs), to babies born prematurely or with medical complications.

Analyst Recommendations for Mednax (NYSE:MD)

Receive News & Ratings for Mednax Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mednax Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.